On­coMed’s bad, no good, dis­as­trous month con­tin­ues as an­oth­er PhII flops, PhIb tri­al is shut­tered

A few days ago, shares of On­coMed $OMED were blitzed by the news that its top drug dem­cizum­ab had flopped in a Phase II study, fol­low­ing it up with the news that Bay­er by­passed a tie-up on two oth­er key pro­grams. This morn­ing the biotech added that its drug tarex­tum­ab plus chemo al­so failed a Phase II study. And in­ves­ti­ga­tors de­cid­ed to drop a Phase Ib tri­al of bron­tic­tuzum­ab af­ter they de­ter­mined that the drug reg­i­men was not tol­er­at­ed by pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.